🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Cologne
Clinical trial register · Germany

Clinical Trials in Cologne, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Germany and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5051 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:51 UTC
5051
Studies in scope
all four open statuses
2882
Recruiting now
open to new participants
988
Lead sponsors
across recruiting studies
Top sites
Berlin 1584 Hamburg 889 Essen 760 Dresden 707 Heidelberg 627
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca48 Novartis Pharmaceuticals29 University of Cologne25 Janssen Research & Development, LLC21 Bristol-Myers Squibb21
Site location
Berlin1584 Hamburg889 Essen760 Dresden707 Heidelberg627
All 635 locations
Target enrolment
to

Trials with a site in Cologne

612 of 5051 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Germany
Start
Recruiting
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
NCT07213804Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Neoplasm Metastasis
DrugsMIRV·Pegylated liposomal doxorubicin·Topotecan·Gemcitabine
Eli Lilly and Company
Phase 3
1,630
Aachen, Berlin, Bonn, Cologne, Dresden, Düsseldorf, Erlangen, Essen
2025-10-22
Recruiting
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
NCT07207811Transthyretin Amyloid Cardiomyopathy (ATTR CM)
DrugNNC6019-0001
Novo Nordisk A/S
Phase 3
1,280
Bad Oeynhausen, Berlin, Cologne, Dresden, Frankfurt am Main, Freiburg im Breisgau, Jena, Kiel
2025-10-02
Recruiting
#AWARE.HIV Europe: Supporting Healthcare Professionals to Find Undiagnosed HIV in European Hospitals: An Effectiveness-implementation Trial.
NCT06900829HIV Infection, HIV, Stigma, Education
Casper Rokx
Not applicable
5,200
Berlin, Cologne, München
2025-10-01
Recruiting
Treatment Guided by Comprehensive Genome and Transcriptome Analysis Versus Standard of Care in Advanced Rare Cancers
NCT06855134Rare Cancer
German Cancer Research Center
Observational
946
Augsburg, Berlin, Cologne, Dresden, Erlangen, Essen, Freiburg im Breisgau, Hamburg
2025-09-29
Recruiting
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
NCT07181109High Risk Cardiovascular Disease, Hypertension, High Cardiovascular Risk
DrugZilebesiran
Alnylam Pharmaceuticals
Phase 3
11,000
Aachen, Ahaus, Altenburg, Bad Homburg, Berlin, Brandenburg an der Havel, Bremen, Cologne
2025-09-22
Recruiting
Impella Pump Return Study to Analyze Deposits and Biomaterial in Used Pumps
NCT06765226Heart Failure
Abiomed Inc.
Observational
200
Heidelberg, Düsseldorf, Dresden, Leipzig, Berlin, Cologne, Essen
2025-09-21
Recruiting
A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseases
NCT06806592Interstitial Lung Diseases, Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases
DrugNerandomilast
Boehringer Ingelheim
Phase 3
400
Berlin, Bonn, Braunschweig, Bremen, Cologne, Düsseldorf, Essen, Freiburg im Breisgau
2025-09-13
Recruiting
A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
NCT06919965Non-Muscle Invasive Bladder Neoplasms
DrugsErdafitinib·Mitomycin C·Gemcitabine
Janssen Research & Development, LLC
Phase 3
220
Cologne, Herne, Leverkusen, Mannheim, Nürtingen, Regensburg
2025-09-10
Recruiting
A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
NCT06855771Carcinoma, Non-Small-Cell Lung
DrugsNavlimetostat·Iza-bren
Bristol-Myers Squibb
Phase 2
182
München, Frankfurt am Main, Halle, Cologne, Würzburg
2025-09-09
Recruiting
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT06973187Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugsTacabrutideg·Pirtobrutinib
BeOne Medicines
Phase 3
500
Bochum, Bonn, Cologne, Dortmund, Karlsruhe, Lübeck, Stuttgart, Ulm
2025-09-04
Not yet open
Immune-Marker Platform for Patients With Advanced Lung Cancer
NCT07150598NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC Stage IIIB~IV, NSCLC Non-small Cell Lung Cancer
Technische Universität Dresden
Observational
500
Cologne, Dresden
2025-09-01
Recruiting
A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections.
NCT06925321Invasive Mold Infections
DrugFosmanogepix
Basilea Pharmaceutica
Phase 3
234
Ulm, Cologne, Mainz, Frankfurt
2025-08-26
Recruiting
An International Observational Study of Adults With Acute Infection
NCT07069400Infectious Disease
University of Minnesota
Observational
1,500
Cologne
2025-08-25
Recruiting
A Study to Assess Safety and Tolerability and to Explore Efficacy of NSC001 in Mild to Moderate Alzheimer's Disease
NCT06995573Alzheimer Disease
NSC-Therapeutics
Phase 1/2
90
Altenburg, Bad Homburg, Cologne, Göttingen, Mannheim, Ratingen
2025-08-25
Recruiting
AGENT DCB STANCE: Safety and Effectiveness Study of AGENT Drug-Coated Balloon Compared to Standard of Care Percutaneous Coronary Intervention (PCI) Treatment for de Novo Coronary Lesions
NCT06959524Coronary Arterial Disease (CAD), de Novo Lesions in Native Coronary Arteries
Boston Scientific Corporation
Not applicable
1,616
Cologne, Lahr, Trier
2025-08-21
Active, closed
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
NCT07005128Small-cell Lung Cancer, Extensive Stage Small-cell Lung Cancer
DrugsTarlatamab·Etoposide·Durvalumab·Carboplatin
Amgen
Phase 3
350
Chemnitz, Cologne, Dresden, Essen, Frankfurt am Main, Gauting, Großhansdorf, Kiel
2025-08-18
Recruiting
SCORE Study: Comparing Surgery and Rigid Collar Treatment for Odontoid Fractures in Adults Over 70
NCT06961578Odontoid Fracture, Elderly
Technical University of Munich
Not applicable
322
Munich, Frankfurt am Main, Berlin, Aachen, Cologne, Dresden, Essen, Göttingen
2025-08-13
Recruiting
Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study
NCT07264426Chronic Inflammatory Demyelinating Polyradiculoneuropathy, CIDP, CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)
DrugEfgartigimod PH20
argenx
Observational
200
Berlin, Bochum, Cologne, Düsseldorf, Frankfurt, Giessen, Göttingen, Hamburg
2025-08-11
Recruiting
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
NCT06952803Prostate Cancer
DrugsPrednisolone/Prednisone·Saruparib·Abiraterone
AstraZeneca
Phase 3
700
Augsburg, Berlin, Braunschweig, Cologne, Dresden, Duisburg, Düsseldorf, Essen
2025-08-06
Not yet open
Pembrolizumab in First-Line Treatment of Advanced-Stage Classical Hodgkin Lymphoma
NCT06045195Hodgkin Lymphoma
DrugPembrolizumab
University of Cologne
Phase 2
40
Cologne
2025-08
Recruiting
A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months
NCT07126262Hypochondroplasia
DrugVosoritide
BioMarin Pharmaceutical
Phase 2
60
Cologne, Homburg, Magdeburg
2025-07-30
Recruiting
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
NCT06976203Alzheimer's Disease
DrugsKarX-EC·KarXT
Bristol-Myers Squibb
Phase 3
586
Munich, Göttingen, Bad Homburg, Chemnitz, Cologne, Ulm
2025-07-21
Recruiting
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
NCT06570798Systemic Lupus Erythematosus, Active Refractory Rheumatoid Arthritis
DrugsUplizna·Inebilizumab·Blinatumomab
Amgen
Phase 2
220
Cologne, Düsseldorf, Leipzig, München
2025-07-16
Recruiting
A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised
NCT07013474COVID-19 Infection
DrugsIbuzatrelvir·Remdesivir
Pfizer
Phase 3
300
München, Cologne, Hamburg, Rostock, Trier, Villingen-Schwenningen, Wuppertal
2025-07-14
Active, closed
A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)
NCT07015983Lupus Erythematosus, Systemic, Lupus Nephritis
DrugsZola-cel·Fludarabine·Cyclophosphamide
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 2
89
Leipzig, Magdeburg, Berlin, Cologne, Erlangen, Herne
2025-07-14
Recruiting
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
NCT07052903Transthyretin Amyloidosis With Cardiomyopathy
DrugNucresiran
Alnylam Pharmaceuticals
Phase 3
1,750
Berlin, Cologne, Dresden, Göttingen, Hanover, Heidelberg, Leipzig, Magdeburg
2025-07-02
Active, closed
Rezafungin for Treatment of Chronic Pulmonary Aspergillosis (CPA) in Adults With Limited Treatment Options
NCT06794554Chronic Pulmonary Aspergillosis
Mundipharma Research Limited
Phase 2
60
Berlin, Cologne, Gauting
2025-06-30
By invitation
Long-Term Extension Study of Vosoritide to Treat Children With Hypochondroplasia
NCT07073014Hypochondroplasia
DrugVosoritide
BioMarin Pharmaceutical
Phase 3
140
Homburg, Cologne, Magdeburg
2025-06-20
Recruiting
A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis
NCT06972446Rheumatoid Arthritis
DrugsABBV-8736·ABBV-701·Lutikizumab·Adalimumab
AbbVie
Phase 2
180
Wetzlar, Bonn, Cologne, Hamburg
2025-06-20
Active, closed
A Study to Assess Safety, Cellular Kinetics and Exploratory Efficacy of Rapcabtagene Autoleucel in Rheumatoid Arthritis and Sjogren's Disease
NCT07048197Rheumatoid Arthritis (RA) and Sjögren's Disease (SjD)
DrugRapcabtagene autoleucel
Novartis Pharmaceuticals
Phase 1/2
27
Freiburg im Breisgau, Göttingen, Cologne, Berlin, Ulm
2025-06-20
Recruiting
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
NCT06943872Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugsSonrotoclax·Venclexta·Obinutuzumab·Venetoclax
BeOne Medicines
Phase 3
630
Berlin, Cologne, Dresden, Jena, Kiel, Mutlangen, München, Neubrandenburg
2025-06-11
Recruiting
The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
NCT06872892Bronchiectasis
DrugVerducatib
Boehringer Ingelheim
Phase 3
1,755
Aachen, Ahrensburg, Bamberg, Berlin, Bochum, Bonn, Cologne, Donaustauf
2025-06-09
Recruiting
ANCHOR Study: A Study to Assess the Safety and Efficacy of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
NCT06902558Autosomal Dominant Polycystic Kidney Disease
Calico Life Sciences LLC
Phase 2
240
Heidelberg, Munich, Hanover, Cologne, Berlin
2025-06-09
Active, closed
A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy
NCT06821542Chronic Graft-versus-host-disease
DrugAxatilimab
Incyte Corporation
Phase 3
9
Aachen, Berlin, Cologne, Dresden, Erlangen, Frankfurt am Main, Freiburg im Breisgau, Göttingen
2025-06-04
Recruiting
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT06852222Leukemia, Myeloid, Acute
DrugsBleximenib·Azacitidine·Venetoclax
Janssen Research & Development, LLC
Phase 3
600
Augsburg, Cologne, Dresden, Frankfurt, Freiburg im Breisgau, Hamburg, Heidelberg, Kiel
2025-06-04
Recruiting
A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)
NCT06961006Malignant Melanoma
DrugsIntismeran autogene·Keytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 2
160
Heidelberg, Frankfurt am Main, Cologne, Essen, Hamburg
2025-05-29
Recruiting
A Study of Patients With Lower Extremity Acute Limb Ischemia to Remove Thrombus With the Indigo™ Aspiration System (STRIDE II)
NCT06747117Lower Extremity Acute Limb Ischemia, LE ALI
Penumbra Inc.
Observational
300
Cologne, Leipzig, Stuttgart
2025-05-18
Active, closed
Study of GS-0151 in Participants With Rheumatoid Arthritis
NCT06902519Rheumatoid Arthritis
Gilead Sciences
Phase 1
65
Cologne, Hamburg, München
2025-05-14
Recruiting
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
NCT06925737Prostate Cancer, Prostatic Neoplasms
DrugsIfinatamab Deruxtecan·Prednisone·Docetaxel
Merck Sharp & Dohme LLC
Phase 3
1,440
Nürtingen, Stuttgart, Munich, Nuremberg, Frankfurt am Main, Cologne, Duisburg, Lübeck
2025-05-13
Recruiting
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
NCT06916806Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis
DrugAZD5492
AstraZeneca
Phase 1
72
Cologne, Erlangen, Magdeburg
2025-05-01
Active, closed
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
NCT06948435Hypertension, Overweight or Obesity
DrugOrforglipron
Eli Lilly and Company
Phase 3
487
Bad Homburg, Berlin, Cologne, Dresden, Essen, Leipzig, Oldenburg
2025-04-30
Active, closed
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
NCT06952530Hypertension
DrugOrforglipron
Eli Lilly and Company
Phase 3
487
Bad Homburg, Berlin, Cologne, Dresden, Essen, Leipzig, Oldenburg
2025-04-30
Active, closed
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
NCT06948422Hypertension
DrugOrforglipron
Eli Lilly and Company
Phase 3
974
Bad Homburg, Berlin, Cologne, Dresden, Essen, Leipzig, Oldenburg
2025-04-30
Recruiting
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
NCT06875310Carcinoma, Non-Small-Cell Lung
DrugsAdagrasib·Pemetrexed·Cisplatin·Carboplatin
Mirati Therapeutics Inc.
Phase 3
630
Esslingen am Neckar, Ulm, München, Frankfurt am Main, Giessen, Hanover, Oldenburg, Cologne
2025-04-24
Active, closed
A Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants With Sjögren's
NCT06928142Sjogren Disease
DrugSibeprenlimab
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 2
83
Freiburg im Breisgau, Cologne, Hamburg, München
2025-04-23
Active, closed
Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)
NCT06814145Hypertension, Pulmonary
DrugSotatercept
Merck Sharp & Dohme LLC
Phase 2
440
Heidelberg, München, Giessen, Cologne, Mainz, Dresden, Berlin
2025-04-16
Recruiting
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
NCT06790693Breast Cancer
DrugsCDK4/6i·Inavolisib·Letrozole
Hoffmann-La Roche
Phase 3
450
Cologne, Dresden, Essen, Hamburg, Hanover, Heidelberg, Koblenz, Langen
2025-04-09
Recruiting
The Dragon PLC Trial (DRAGON-PLC)
NCT06914648Primary Liver Cancer, Hepatocellular Carcinoma (HCC), Cholangiocarcinoma
Maastricht University
Not applicable
358
Cologne, Dresden, Hanover
2025-04-01
Not yet open
Pre-Operative Treatment in REseCTable COlon CanceR
NCT06899477Colo-rectal Cancer, Colon Cancer, Colon Carcinoma
DrugsMFOLFOXIRI·MFOLFOX6·Folfox·Irinotecan
Dominik Paul Modest
Phase 3
714
Berlin, Berlin-Spandau, Chemnitz, Cologne, Dessau, Dortmund, Frankfurt, Hamburg
2025-04
Recruiting
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
NCT06890598Carcinoma, Non-Small-Cell Lung
DrugsOlomorasib·Durvalumab·Pembrolizumab
Eli Lilly and Company
Phase 3
700
Berlin, Chemnitz, Cologne, Donauwörth, Erfurt, Gauting, Georgsmarienhütte, Großhansdorf
2025-03-27
Recruiting
Vaccine-induced Immunity in Immunocompromised Patients
NCT06612515Immunodeficiency
University of Cologne
Observational
1,000
Cologne
2025-03-25
Active, closed
Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)
NCT06726265Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
DrugsEfti·Pemetrexed·Keytruda·Paclitaxel
Immutep S.A.S.
Phase 3
756
Amberg, Augsburg, Bad Saarow, Berlin, Cologne, Frankfurt, Frankfurt am Main, Gauting
2025-03-21
Active, closed
A Pivotal Study of N-Acetyl-L-Leucine on Ataxia-Telangiectasia (A-T)
NCT06673056Ataxia-Telangiectasia, Ataxia-Telangiectasia (A-T)
DrugN-Acetyl-L-Leucine
IntraBio Inc
Phase 3
60
Cologne, Giessen
2025-03-18
Not yet open
Early Recovery After Surgery (ERAS)/Prehabilitation - Randomized Controlled Trial on the Implementation of ERAS/prehabilitation in Elective Reconstructive Shoulder Surgery
NCT06868472Rotator Cuff
Prof. Arasch Wafaisade
Not applicable
84
Cologne
2025-03-18
Recruiting
A Study to Learn About How Safe BAY 3389934 is, Its Suitable Dose, and How it Affects the Participants With Sepsis Induced Coagulopathy
NCT06854640Sepsis, Coagulopathy
DrugBAY3389934
Bayer
Phase 1
36
München, Cologne, Dresden, Leipzig
2025-03-12
Recruiting
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
NCT06925542SLE (Systemic Lupus), Lupus Erythematosus, Systemic, Lupus Nephritis, Systemic Sclerosis
DrugZugo-cel
CRISPR Therapeutics
Phase 1
80
Augsburg, Cologne, Hanover, Mainz
2025-03-10
Recruiting
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
NCT06772623Non Small Cell Lung Carcinoma
DrugsBudigalimab·Telisotuzumab Adizutecan·Pemetrexed·Cisplatin
AbbVie
Phase 1/2
252
Freiburg im Breisgau, Heilbronn, Augsburg, Würzburg, Frankfurt am Main, Cologne, Hemer, Oldenburg in Holstein
2025-03-06
Recruiting
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
NCT06806033Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma
DrugsGlofitamab·Obinutuzumab·Oxaliplatin·Gemcitabine
Hoffmann-La Roche
Phase 2
130
Berlin, Cologne, Magdeburg
2025-03-05
Recruiting
A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2)
NCT06796907Tumours, Gynecological
DrugsMo-Rez·Dostarlimab·Bevacizumab
GlaxoSmithKline
Phase 1/2
305
Cologne, Leipzig, Mainz, München
2025-03-04
By invitation
Assessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0
NCT06823115Acute Kidney Injury, Fluid Overload, Prematurity Complications, Risk Factors
Indiana University
Observational
4,000
Cologne
2025-03-01
Recruiting
S-ICD Implantation: US Based Pilot Study
NCT06771700Sudden Cardiac Death
Universitätsklinikum Köln
Not applicable
20
Cologne
2025-03-01
Recruiting
Study to Assess Change in Disease Activity of Risankizumab Treatment in Adult Participants With Moderate to Severe Ulcerative Colitis
NCT06764706Ulcerative Colitis
AbbVie
Observational
200
Heidelberg, Potsdam, Tostedt, Hanover, Schwerin, Ahaus, Bochum, Cologne
2025-02-27
Recruiting
A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
NCT06646276Extensive-Stage Small Cell Lung Cancer
DrugsEtoposide·Atezolizumab·Nivolumab·Carboplatin
Bristol-Myers Squibb
Phase 3
530
Frankfurt am Main, Oldenburg, Cologne, Halle, Bad Berka, Gauting, Großhansdorf, Heidelberg
2025-02-25
Recruiting
Efficacy of Add-on Plasma Exchange As an Adjunctive Strategy Against Septic Shock
NCT05726825Septic Shock
Hannover Medical School
Not applicable
274
Berlin, Bonn, Braunschweig, Bremerhaven, Cologne, Erlangen, Essen, Halle
2025-02-19
Recruiting
FMRI-neurofeedback in Parkinson's Disease
NCT06582355Parkinson Disease
Maastricht University Medical Center
Not applicable
60
Cologne
2025-02-10
Recruiting
Cyclosporine In Takotsubo Syndrome
NCT05946772Takotsubo Cardiomyopathy
DrugCyclosporine A
University Hospital Heidelberg
Phase 2
204
Bad Nauheim, Berlin, Bonn, Cologne, Dresden, Düsseldorf, Essen, Frankfurt
2025-02-01
Recruiting
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
NCT06564038Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma, Large B-cell Lymphoma
DrugsSurovatamig·Acalabrutinib·Vincristine·Doxorubicin
AstraZeneca
Phase 1/2
408
Cologne, Homburg, Kiel, Mainz, München, Würzburg
2025-01-30
Recruiting
Colorectal Resections in Patients With Retroperitoneal Sarcoma
NCT06943612Sarcoma, Soft Tissue, Retroperitoneal Sarcoma
Heidelberg University
Observational
120
Mannheim, Göttingen, Berlin, Cologne, Dresden, Erlangen, Greifswald, Halle
2025-01-27
Recruiting
Trial Comparing Cataract Surgery With Triple-DMEK in Patients With Cataract and Fuchs Endothelial Corneal Dystrophy
NCT06425666Cataract Surgery, Cataract and Fuchs Endothelial Corneal Dystrophy
University of Cologne
Not applicable
120
Cologne
2025-01-24
Recruiting
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
NCT06743126Melanoma, Cutaneous Malignant
DrugsAnzu-cel·Lifileucel·Temodar·Dacarbazine
Immatics US, Inc.
Phase 3
360
Cologne, Berlin, Bonn, Dresden, Erlangen, Essen, Frankfurt am Main, Hamburg
2025-01-14
Recruiting
A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis
NCT06807424Arthritis, Psoriatic
DrugIcotrokinra
Janssen Research & Development, LLC
Phase 3
750
Berlin, Cologne, Dresden, Freiburg im Breisgau, Hamburg, Herne, Langenau, Ratingen
2025-01-09
Recruiting
Photodynamic Therapy of Primary Localized Prostate Cancer With the SpectraCure P18 System
NCT06807359Prostate Cancer
DrugVerteporfin
SpectraCure AB
Phase 1/2
43
Cologne, Rostock
2025-01-06
Recruiting
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT06588478Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugPirtobrutinib
Loxo Oncology, Inc.
Phase 2
249
Cologne, Frankfurt, Göttingen, Hanover, Hösbach, Koblenz
2025-01-03
Active, closed
Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease
NCT06747572Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Vertex Pharmaceuticals Incorporated
Observational
401
Berlin, Cologne
2024-12-19
Active, closed
Phase 2 Study of Rapcabtagene Autoleucel in Myositis
NCT06665256Idiopathic Inflammatory Myopathies
DrugRapcabtagene autoleucel
Novartis Pharmaceuticals
Phase 2
21
Cologne, Leipzig, Jena, Aachen, Hamburg, Mainz, Nuremberg, Ulm
2024-12-17
Recruiting
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
NCT06679101Multiple Myeloma, Newly Diagnosed Multiple Myeloma
DrugsBelantamab mafodotin·Daratumumab·Lenalidomide·Dexamethasone
GlaxoSmithKline
Phase 3
520
Jena, Lübeck, Chemnitz, Cologne, Dresden, Hamburg, Hanover, Mainz
2024-12-16
Recruiting
REdo Transcatheter Aortic VALVE Implantation for the Management of Transcatheter Aortic Valve Failure
NCT06557798Aortic Valve Stenosis
The Leeds Teaching Hospitals NHS Trust
Observational
550
Bad Nauheim, Bad Oeynhausen, Berlin, Cologne, Dortmund, Dresden, Düsseldorf, Frankfurt
2024-12-12
Active, closed
A Study to Evaluate the Safety, Tolerability, and Effects on Blood and Urine Markers of Single Ascending Dose of GSK4771261 in Healthy Participants and Participants With Autosomal Dominant Polycystic Kidney Disease
NCT06734234Kidney Disease
GlaxoSmithKline
Phase 1
86
Cologne, Lübeck
2024-12-11
Recruiting
A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.
NCT05421858Candidemia, Candidiasis, Invasive
DrugsCaspofungin·Fosmanogepix·Fluconazole
Basilea Pharmaceutica
Phase 3
450
Ulm, Regensburg, Frankfurt am Main, Giessen, Cologne, Heidelberg
2024-12-11
Recruiting
A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease
NCT06679140COVID-19 SARS-CoV-2 Infection
DrugIbuzatrelvir
Pfizer
Phase 3
2,330
Munich, Frankfurt am Main, Obertshausen, Cologne, Augsburg, Berlin, Freiburg im Breisgau, Hamburg
2024-12-08
Active, closed
Nipocalimab in Moderate to Severe Sjogren's Disease
NCT06741969Sjogrens Syndrome
DrugNipocalimab
Janssen Research & Development, LLC
Phase 3
655
Cologne, Dresden, Erlangen, Freiburg im Breisgau, Hamburg, Hanover, Herne, München
2024-12-04
Recruiting
Capivasertib Plus Fulvestrant vs. Fulvestrant in Primary High-risk Lobular Breast Cancer
NCT06607757CCCA Assessed by Ki67 Drop Below <2.7% From Baseline
DrugsCapivasertib·Fulvestrant
GBG Forschungs GmbH
Phase 2
120
Augsburg, Berlin, Bielefeld, Bremen, Cologne, Cottbus, Dortmund, Essen
2024-12-04
Active, closed
A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1
NCT06694805HIV Infections
DrugsRpv La·Cabotegravir·B/F/TAF
ViiV Healthcare
Phase 3
326
Cologne, Berlin, Düsseldorf, Frankfurt
2024-12-02
Recruiting
A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)
NCT06667700Coronavirus Disease (COVID-19)
DrugMolnupiravir
Merck Sharp & Dohme LLC
Phase 3
3,082
Munich, Frankfurt am Main, Cologne, Berlin
2024-12-02
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
NCT06627647Non-squamous Non-small Cell Lung Cancer
DrugsRilvegostomig·Pemetrexed·Keytruda·Cisplatin
AstraZeneca
Phase 3
1,160
Bad Berka, Berlin, Bielefeld, Bochum, Chemnitz, Cologne, Esslingen am Neckar, Frankfurt
2024-11-27
Active, closed
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56
NCT06683742Wet Age Related Macular Degeneration, wAMD
DrugsEYP-1901·Aflibercept
EyePoint Pharmaceuticals, Inc.
Phase 3
400
Cologne
2024-11-27
Recruiting
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
NCT06617325Systemic Lupus Erythematosus
UCB Biopharma SRL
Phase 3
450
Berlin, Cologne, Dessau, Dresden, Freiburg im Breisgau, Greifswald, Herne, Jena
2024-11-21
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
NCT06692738Non-small Cell Lung Cancer
DrugsRilvegostomig·Nab-paclitaxel·Keytruda·Paclitaxel
AstraZeneca
Phase 3
1,160
Bad Berka, Berlin, Bielefeld, Bochum, Chemnitz, Cologne, Essen, Esslingen am Neckar
2024-11-18
Recruiting
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
NCT06632457Metabolic Dysfunction Associated Steatohepatitis
Boehringer Ingelheim
Phase 3
1,590
Berlin, Bochum, Cologne, Dresden, Frankfurt, Heidelberg, Homburg, Landshut
2024-11-12
Recruiting
A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study
NCT06531499Metastatic Castration-Resistant Prostate Cancer
DrugLu-PSMA
Novartis Pharmaceuticals
Phase 1
106
Cologne, Wuppertal, Aachen, Berlin, Essen, München, Rostock
2024-11-11
Active, closed
A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity
NCT06662383Obesity
DrugsRetatrutide·Tirzepatide
Eli Lilly and Company
Phase 3
800
Villingen-Schwenningen, Lingen, Cologne, Essen, Leipzig, Oldenburg in Holstein, Hamburg
2024-11-01
Recruiting
FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations
NCT06669117Solid Tumor, MET Alteration
Pierre Fabre Medicament
Phase 1/2
140
Cologne, Dresden
2024-10-22
Recruiting
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
NCT06562192Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, HR+/HER2- Ductal and Lobular Breast Cancer, Triple Negative Breast Cancer
Novartis Pharmaceuticals
Phase 1
162
Cologne, Essen, München, Rostock
2024-10-15
Recruiting
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
NCT06632444Metabolic Dysfunction Associated Steatohepatitis (MASH), Liver Fibrosis
Boehringer Ingelheim
Phase 3
1,800
Berlin, Bochum, Cologne, Dresden, Erlangen, Frankfurt, Heidelberg, Homburg
2024-10-14
Recruiting
A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy
NCT05460000Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Clear Cell Carcinoma
North Eastern German Society of Gynaecological Oncology
Phase 2
640
Aachen, Baden-Baden, Berlin, Bonn, Cologne, Detmold, Dortmund, Dresden
2024-10-11
Active, closed
Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1
NCT06630286HIV-1-infection
DrugsISL/LEN·B/F/TAF
Gilead Sciences
Phase 3
609
Berlin, Bonn, Cologne, Essen, Hamburg
2024-10-09
By invitation
Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC)
NCT06419179Small Cell Lung Carcinoma
DrugsOlaparib·Durvalumab
University of Cologne
Phase 2
29
Cologne
2024-10-09
Active, closed
Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1
NCT06630299HIV-1-Infection
DrugsAntiretroviral Combinations·ISL/LEN
Gilead Sciences
Phase 3
600
Cologne, Hanover, Mannheim, München
2024-10-08
Recruiting
Efficacy of INM004 in Children With STEC-HUS
NCT06389474Hemolytic-Uremic Syndrome
Inmunova S.A.
Phase 3
220
Berlin, Cologne, Heidelberg
2024-10-05
Recruiting
Hair Cortisol as Marker of Chronic Stress in Preterm and Term Fathers - Fathair-study
NCT05969431Stress, Psychological, Father-Child Relations, Premature Birth
University of Cologne
Observational
120
Cologne
2024-10-01
Rows per page Showing 101–200 of 612
Previous 1 2 3 4 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a German investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 29 September 2026. https://priyalifescience.com/clinical-trials-germany/city/cologne?page=2

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Germany and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,051 studies in total at the last sync on 26 Sep 2026, 19:51 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 612 of those studies with a site in Cologne.

How many clinical trials are recruiting in Cologne?

312 of the 612 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:51 UTC sync. A further 27 have not yet opened recruitment, 261 are active but closed to new participants, and 12 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.